The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for
Hepatocellular Carcinoma Page 1 1 International Liver Cancer Association (ILCA) White Paper …

Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …

This report explores the available curative molecules directed against hepatocellular
carcinoma (HCC). Limited efficiency as well as other drawbacks of existing molecules led to …

The knowledge and understanding of all aspects of liver cancer [this including
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have …

Background & Aims Sorafenib, an oral multikinase inhibitor, significantly prolonged overall
survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in …

Summary Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown
promising antitumour activity in hepatocellular carcinoma as monotherapy and in …